A segmented release probiotic capsule

Abstract

The present application relates to the technical field of health products, in particular to a segmented-release probiotic capsule, comprising a capsule body and a plurality of granules arranged in the capsule body, wherein the granules comprise a first skeleton, a second skeleton, a third skeleton, a first drug arranged in the first skeleton, a second drug arranged in the second skeleton, and a third drug arranged in the third skeleton, and the thickness of the first skeleton, the second skeleton and the third skeleton increases in turn. The present application has differences in the thickness of the first skeleton, the second skeleton and the third skeleton, so that the melting time of the three in the intestinal tract is different, achieving the effect of segmented-release probiotics, and prolonging the duration of probiotics.

Description

Technical Field

[0001] This invention relates to the field of health product technology, and in particular to a probiotic capsule with segmented release. Background Technology

[0002] Most probiotic products on the market are currently available in the form of powder, capsules, or sedatives. However, after entering the human body, these products are easily affected by stomach acid and digestive enzymes, reducing the survival rate of probiotics and resulting in less than expected efficacy. In addition, many probiotic capsules release probiotics quickly after the outer capsule dissolves, resulting in a short duration of probiotic retention in the intestines and insufficiently lasting effects. Summary of the Invention

[0003] This invention addresses the problems of existing technologies by providing a segmented-release probiotic capsule. Through structural optimization, different types of particles can be released at different time periods, thereby extending the duration of probiotic effects.

[0004] To solve the above-mentioned technical problems, the present invention adopts the following technical solution:

[0005] The present invention provides a segmented release probiotic capsule, comprising a capsule body and a plurality of particles disposed within the capsule body. The particles include a first skeleton, a second skeleton, a third skeleton, a first drug disposed within the first skeleton, a second drug disposed within the second skeleton, and a third drug disposed within the third skeleton. The thickness of the first skeleton, the thickness of the second skeleton, and the thickness of the third skeleton increase sequentially.

[0006] Furthermore, the particle size of the first skeleton is 0.9-1.1 mm, the particle size of the second skeleton is 1-1.2 mm, and the particle size of the third skeleton is 1.1-1.3 mm.

[0007] Furthermore, the first drug includes a first multi-probiotic and a nutrient source, the second drug includes a second multi-probiotic and a nutrient source, and the third drug includes a third multi-probiotic.

[0008] Furthermore, the first multi-probiotic strain includes acid-fast lactobacillus, with a colony count of 500 million to 1.5 billion.

[0009] Furthermore, the second type of probiotic includes Lactobacillus acidophilus and Lactobacillus rhamnosus, with Lactobacillus acidophilus having a colony count of 1.5-2.5 billion and Lactobacillus rhamnosus having a colony count of 1-1.5 billion.

[0010] Furthermore, the third probiotic includes Bifidobacterium, with a quantity of 3-3.5 billion.

[0011] Furthermore, the first drug also includes digestive enzymes, including at least one of amylase, protease, lipase and lactase. The amylase content is 4500-5300 DU; The content of protease is 9500-11000 HUT; The lipase content is 200-500 FIP; The lactase content is 300-900 ALU.

[0012] Furthermore, the capsule includes a first outer shell and a second outer shell, which are connected to each other, and the drug particles are located between the first outer shell and the second outer shell; the first outer shell is made of a red semi-transparent material, and the second outer shell is made of a transparent material.

[0013] Furthermore, the first skeleton is made of a fast-dissolving material, while the second and third skeletons are both made of a slow-release material.

[0014] Furthermore, the nutrient source includes lactose.

[0015] The beneficial effects of the present invention are as follows: By making the thickness of the first, second, and third skeletons different, the present invention achieves the effect of segmented release of probiotics by making the melting time of the three skeletons in the intestines different, thus making the probiotics last longer. Attached Figure Description

[0016] Fig. 1 This is a schematic diagram of the present invention.

[0017] Fig. 2 This is a schematic diagram of the internal structure of the first skeleton of the present invention.

[0018] Fig. 3 This is a schematic diagram of the interior of the second skeleton of the present invention.

[0019] Fig. 4 This is a schematic diagram of the internal structure of the third skeleton of the present invention.

[0020] Reference numerals: 1—capsule, 2—granule, 3—first skeleton, 4—second skeleton, 5—third skeleton, 6—first drug, 7—second drug, 8—third drug, 9—first shell, 10—second shell. Detailed Implementation

[0021] To facilitate understanding by those skilled in the art, the present invention will be further described below with reference to embodiments and accompanying drawings. The content mentioned in the embodiments is not intended to limit the present invention. The present invention will be described in detail below with reference to the accompanying drawings.

[0022] like Figs. 1 to 4As shown, the present invention provides a segmented release probiotic capsule, comprising a capsule body 1 and a plurality of particles 2 disposed within the capsule body 1. The particles 2 include a first skeleton 3, a second skeleton 4, a third skeleton 5, a first drug 6 disposed within the first skeleton 3, a second drug 7 disposed within the second skeleton 4, and a third drug 8 disposed within the third skeleton 5. The thickness of the first skeleton 3, the thickness of the second skeleton 4, and the thickness of the third skeleton 5 increase sequentially.

[0023] In practical applications, the particle size of the first skeleton 3 is 0.9-1.1 mm, the particle size of the second skeleton 4 is 1-1.2 mm, and the particle size of the third skeleton 5 is 1.1-1.3 mm. For example, preferably, the particle size of the first skeleton 3 is 1 mm, the particle size of the second skeleton 4 is 1.1 mm, and the particle size of the third skeleton 5 is 1.2 mm, and the first skeleton 3, the second skeleton 4, and the third skeleton 5 can all be conventional skeleton materials.

[0024] If the materials of the three skeletons are basically the same, the time it takes for them to melt in the intestine and release the drug will also be different because their thicknesses are different. By using this time difference to control the release time of the first drug 6, the second drug 7 and the third drug 8, the effect of stepwise drug release is achieved.

[0025] The specific mechanism of this invention is as follows: After being ingested, the invention can pass smoothly through the stomach due to the protection of the capsule 1. During gastric acid digestion, the capsule 1 is dissolved, releasing the first skeleton 3, the second skeleton 4, and the third skeleton 5. After digestion by gastric acid, the thinnest first skeleton 3 is dissolved in the anterior part of the small intestine, releasing the first drug 6, which then exerts its effect at this location.

[0026] Because of their greater thickness, the second and third skeletons 4 and 5 can continue to move forward under the peristalsis of the small intestine. After about 5.5 hours, the second and third skeletons 4 and 5 will reach the posterior end of the small intestine / ileocecal junction, where the second skeleton 4 will be completely dissolved, thus releasing the second drug 7.

[0027] After undergoing the above process, the thickness of the third framework 5 will decrease, but it will still be able to completely encapsulate the third drug 8, allowing the third framework 5 to continue moving with intestinal peristalsis. Thus, after approximately 12.5 hours, the third framework 5 will dissolve and release the third drug 8 when it moves to the proximal part of the large intestine, allowing the third drug 8 to be released at the proximal part of the large intestine.

[0028] This invention creates a thickness difference in the skeletons of different drugs, allowing them to be released at different locations, thereby avoiding the simultaneous and excessive release of drugs that would result in an overly strong and short-lasting effect.

[0029] In this embodiment, the first drug 6 includes a first multi-component probiotic and a nutrient source, the second drug 7 includes a second multi-component probiotic and a nutrient source, and the third drug 8 includes a third multi-component probiotic.

[0030] Furthermore, the first drug 6 includes a first multi-probiotic and a nutrient source, the second drug 7 includes a second multi-probiotic and a nutrient source, and the third drug 8 includes a third multi-probiotic.

[0031] The first multi-component probiotic includes acid-fast Lactobacillus, with a colony count of 500-1.5 billion. Since the first drug 6 is released in the pre-intestinal tract, and individual constitutions vary, some of the first framework 3 may be dissolved in the terminal stomach, causing premature release of the first drug 6. Using acid-fast Lactobacillus as the first multi-component probiotic effectively resists gastric acid corrosion, allowing the first multi-component probiotic to successfully reach the small intestine and exert its effect, thus ensuring the effectiveness of the first release.

[0032] Specifically, depending on the needs of different individuals, the first drug may also be equipped with corresponding digestive enzymes, specifically: the first drug also includes digestive enzymes, which include at least one of amylase, protease, lipase and lactase. The amylase content is 4500-5300 DU; The content of protease is 9500-11000 HUT; The lipase content is 200-500 FIP; The lactase content is 300-900 ALU.

[0033] DU, HUT, FIP, and ALU are all commonly used units of measurement in the pharmaceutical industry and will not be elaborated upon here. By incorporating relevant enzymes into the first drug 6 according to the needs of the target population, the effects of this invention can be made more complex.

[0034] Specifically, the second type of probiotic includes Lactobacillus acidophilus and Lactobacillus rhamnosus, with Lactobacillus acidophilus having a colony count of 1.5-2.5 billion and Lactobacillus rhamnosus having a colony count of 1-1.5 billion.

[0035] The total number of probiotics released by the second drug 7 is preferably 3-4 billion CFU (colony count) to ensure the effectiveness of the second drug 7.

[0036] Furthermore, the third probiotic includes Bifidobacterium, with a quantity of 3-3.5 billion.

[0037] Specifically, the nutrient source includes lactose. Lactose can effectively enhance the activity of various probiotics, resulting in better probiotic efficacy. The following guidelines can be used as a reference: For infants aged 6 months to 2 years, the total lactose content of drug 6 (first drug), drug 7 (second drug), and drug 8 (third drug) should be 50-100 mg; for children aged 2-6 years, the total lactose content should be 100-200 mg; for users over 6 years old, the total lactose content should be 200-500 mg.

[0038] In this embodiment, the capsule 1 includes a first outer shell 9 and a second outer shell 10, the first outer shell 9 and the second outer shell 10 are connected to each other, and the drug particles are located between the first outer shell 9 and the second outer shell 10; the first outer shell 9 is made of red semi-transparent material, and the second outer shell 10 is made of transparent material.

[0039] Both the first outer shell 9 and the second outer shell 10 are made of conventional capsule materials. Both are designed to have a certain degree of transparency, allowing the user to observe the contents of the capsule 1 and facilitating identification during production to prevent the inclusion of the drug skeleton due to errors.

[0040] In this embodiment, the first skeleton 3 is made of a fast-dissolving material, and the second skeleton 4 and the third skeleton 5 are both made of a slow-release material.

[0041] Specifically, the skeleton components are also conventional, such as those composed of HPMC, EC, PVA, PLGA, PEG, etc. HPMC is hydroxypropyl methylcellulose, which is mainly used to adjust the dissolution rate and ensure the sustained release effect of the drug; EC is ethyl cellulose, which is a commonly used hydrophobic skeleton material that can enhance the controlled release characteristics; PVA is polyvinyl alcohol, and PLGA is polylactic acid-glycolic acid copolymer. Both are used for microcapsule encapsulation to improve the survival rate of probiotics.

[0042] Generally, after the first matrix 3 is released, it will dissolve rapidly in the anterior part of the small intestine to ensure the release of the first drug 6; while the second matrix 4 will completely dissolve in the posterior part of the small intestine / ileocecal junction 5.5 hours after release to release the second drug 7; and the third matrix 5 will completely dissolve in the proximal part of the large intestine 12 hours after release to release the third drug 8.

[0043] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art can make some changes or modifications to the above-disclosed technical content to create equivalent embodiments without departing from the scope of the present invention. Any simple modifications, equivalent changes, and modifications made to the above embodiments based on the present invention without departing from the scope of the present invention are within the scope of the present invention.

Claims

1. A segmented-release probiotic capsule, comprising a capsule body and a plurality of particles disposed within the capsule body, characterized in that: The particle includes a first skeleton, a second skeleton, a third skeleton, a first drug disposed within the first skeleton, a second drug disposed within the second skeleton, and a third drug disposed within the third skeleton, with the thickness of the first skeleton, the thickness of the second skeleton, and the thickness of the third skeleton increasing sequentially.

2. The segmented-release probiotic capsule according to claim 1, characterized in that: The particle size of the first skeleton is 0.9-1.1 mm, the particle size of the second skeleton is 1-1.2 mm, and the particle size of the third skeleton is 1.1-1.3 mm.

3. The segmented-release probiotic capsule according to claim 1, characterized in that: The first drug includes a first multi-probiotic and a nutrient source, the second drug includes a second multi-probiotic and a nutrient source, and the third drug includes a third multi-probiotic.

4. The segmented-release probiotic capsule according to claim 3, characterized in that: The first multi-probiotic strain includes acid-fast lactobacillus, with a colony count of 500 million to 1.5 billion.

5. The segmented-release probiotic capsule according to claim 3, characterized in that: The second type of probiotic includes Lactobacillus acidophilus and Lactobacillus rhamnosus, with Lactobacillus acidophilus having a colony count of 1.5-2.5 billion and Lactobacillus rhamnosus having a colony count of 1-1.5 billion.

6. The segmented-release probiotic capsule according to claim 3, characterized in that: The third type of probiotic includes Bifidobacterium, with a quantity of 3-3.5 billion.

7. The segmented-release probiotic capsule according to claim 3, characterized in that: The first drug also includes digestive enzymes, including at least one of amylase, protease, lipase and lactase. The amylase content is 4500-5300 DU; The content of protease is 9500-11000 HUT; The lipase content is 200-500 FIP; The lactase content is 300-900 ALU.

8. The segmented-release probiotic capsule according to claim 1, characterized in that: The capsule includes a first outer shell and a second outer shell, which are connected to each other, and the drug particles are located between the first outer shell and the second outer shell; the first outer shell is made of red semi-transparent material, and the second outer shell is made of transparent material.

9. The segmented-release probiotic capsule according to claim 1, characterized in that: The first skeleton is made of a fast-dissolving material, while the second and third skeletons are both made of a slow-release material.

10. The segmented-release probiotic capsule according to claim 3, characterized in that: The nutrient source includes lactose.

Images